Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
翰思艾泰生物醫藥科技(武漢)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3378)

VOLUNTARY ANNOUNCEMENT
HANX BIOPHARMACEUTICALS AND DITU ZHIYUAN INITIATE COOPERATION TO INTRODUCE THE MERITUDIO BIOAI PLATFORM

This announcement is made by the board (the "**Board**") of directors (the "**Directors**") of Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (the "**Company**" or "**Hanx Biopharmaceuticals**") on a voluntary basis.

The Board is pleased to announce that the Company and Suzhou Ditu Zhiyuan Biotechnology Co., Ltd. (蘇州迪途智源生物科技有限公司) ("**Ditu Zhiyuan**") have formally entered into a research cooperation agreement on November 11, 2026.

Hanx Biopharmaceuticals and Ditu Zhiyuan will leverage the Meritudio BioAI cloud platform independently developed by Ditu Zhiyuan to conduct translational and clinical medical research centered on Hanx Biopharmaceuticals' proprietary innovative oncology drug pipeline. By integrating artificial intelligence, multi-omics bioinformatics and clinical medical big data analysis technologies, the collaboration will provide big data support and AI technology guidance for the formulation of preclinical and translational research plans and clinical development strategies for Hanx Biopharmaceutials' innovative drugs.

This research cooperation with Ditu Zhiyuan will further expand the Company's technical collaboration in bioinformatics analysis and data-driven R&D. It is expected to further accelerate the Company's progress in First-in-Class and Best-in-Class drug R&D, and provide strong support for the Company's long-term development and sustainable operations.

About Hanx Biopharmaceuticals

Established in 2014, Hanx Biopharmaceuticals (Wuhan) Co., Ltd. is an innovative biotechnology company dedicated to structural biology, translational medicine and clinical development. The Company is committed to develop next-generation immunotherapies to provide global patients with affordable, safe and effective medical solutions to address the challenges posed by major diseases. Guided by a mission and vision driven by innovation, Hanx Biopharmaceuticals focuses on discovering, developing, and commercializing products for the precision treatment of cancer and autoimmune diseases. The Company strives to satisfy unmet medical needs worldwide, facilitate the prevention, control and mitigation of diseases, and contribute to the global healthcare.

About Ditu Zhiyuan

Located in Suzhou Industrial Park, Suzhou Ditu Zhiyuan Biotechnology Co., Ltd. is an R&D service and software enterprise serving the biopharmaceutical industry, providing professional services for enterprises in artificial intelligence, bioinformatics, statistics, and data science, as well as supporting software development. The Meritudio BioAI integrated platform independently developed by Ditu Zhiyuan helps clients integrate data scattered across experiments, clinical studies, and literature, and transform it into a basis for judgment that can be used for project evaluation, mechanism of action research, and clinical development decision-making. Currently, Ditu Zhiyuan has served a number of pharmaceutical enterprises, covering various scenarios from early-stage R&D to clinical research.

Warning Statement under Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The relevant products may not ultimately be successfully developed and marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
Dr. ZHANG Faming
Chairman and Executive Director

Hong Kong, November 16, 2026

As at the date of this announcement, the Company's Board comprises (i) Dr. Zhang Faming, Dr. Henry Qixiang Li, Ms. Xiao Jieyu and Mr. Liu Min as executive Directors;(ii) Dr. Li Jian as a non-executive Director; and (iii) Dr. Bi Honggang, Mr. Chen Qifeng, Mr. Wong Sai Hung and Dr. Zhang Qiongguang as independent non-executive Directors.